NCT03922997View on ClinicalTrials.gov

A Study to Investigate the Safety and Efficacy of Atezolizumab in Previously-Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

July 3, 2019

Primary Completion Date

August 11, 2022

Study Completion Date

August 11, 2022

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Atezolizumab

Atezolizumab will be administered at a fixed dose of 1200 mg intravenously on the first day of each 21-day cycle.

Trial Locations (7)

100032

Peking Union Medical College Hospital, Beijing

150049

Harbin Medical University Tumor Hospital; Department of Surgery; Pharmacy, Harbin

201315

Fudan University Shanghai Cancer Center; Medical Oncology, Shanghai

310022

Zhejiang Cancer Hospital; Zhejiang Cancer Hospital cancer department, Hangzhou

317000

Taizhou Hospital of Zhejiang Province, Linhai

610041

Sichuan Cancer Hospital, Chengdu

830011

Cancer Hospital Affliated to Xinjiang Medical University, Ürümqi

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT03922997 - A Study to Investigate the Safety and Efficacy of Atezolizumab in Previously-Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter